Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07309380) titled 'Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Shanghai HEP Pharmaceutical Co., Ltd.
Condition:
Hepatitis D, Chronic
Intervention:
Drug: Hepalatide 2.1mg
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: April 2026
Target Sample Size: 150
Countries of Recruitment:
China
To know more, visit https://cl...